Doramapimod

CAS: 285983-48-4

Ref. TR-D534250

Produktinformation

• Name: Doramapimod
• Synonyme: N-[3-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]urea, BIRB 796BS, Birb 796, 1-(3-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-3-(4-(2-(morpholin-4-yl)ethoxy)naphthalen-1-yl)urea, 1-[2-(4-Methylphenyl)-5-tert-butyl-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea, 1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-{4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl}urea, 1-[5-Tert-Butyl-2-(4-Methylphenyl)Pyrazol-3-Yl]-3-[4-(2-Morpholin-4-Ylethoxy)Naphthalen-1-Yl]Urea, Birb 796Bs, Brb 796, N-[3-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N′-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]urea, Unc 10225354, Unc10225354, Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N′-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]-

Beschreibung

Applications Doramapimod is a highly potent inhibitor of p38 mitogen-activated protein kinase (MAPK). Doramapimod is a potential agent for the treatment of inflammatory diseases. Doramapimod blocks baseline and bortezomib-triggered upregulation of p38 MAPK and Hsp27 phosphorylation leading to enhanced cytotoxicity and caspase activation.
References Pargellis, C. et al.: Nat. Struct. Biol., 9, 268 (2002,); Kuma, Y. et al.: J. Biol. CHem., 280, 19472 (2005); Yasui, H. et al.: Br. J. Haematol., 136, 414 (2007);

• Marke: TRC

Chemische Eigenschaften

• Molekulargewicht: 527.66
• Formel: C₃₁H₃₇N₅O₃
• Farbe/Form: Neat
• InChl: InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)
• InChI Key: InChIKey=MVCOAUNKQVWQHZ-UHFFFAOYSA-N
• SMILES: Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1